Nivolumab: A Review in Advanced Melanoma (Q38556639)

4 September 2017

1 reference

title

Nivolumab: A Review in Advanced Melanoma (English)

1 reference

4 September 2017

1

Lesley J Scott

1 reference

4 September 2017

29 July 2015

1 reference

4 September 2017

1 reference

4 September 2017

75

1 reference

4 September 2017

12

1 reference

4 September 2017

1413-1424

1 reference

https://scigraph.springernature.com/pub.10.1007/s40265-015-0442-6

4 September 2017

0 references

cites work

Cost-effectiveness of therapies for melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0442-6

Management options for metastatic melanoma in the era of novel therapies: a primer for the practicing dermatologist: part II: Management of stage IV disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0442-6

Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0442-6

Global cancer statistics, 2012

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0442-6

PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0442-6

Molecular targeted approaches for advanced BRAF V600, N-RAS, c-KIT, and GNAQ melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0442-6

Achievements and challenges of molecular targeted therapy in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0442-6

Immuno-oncology combinations: a review of clinical experience and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0442-6

Clinical impact of checkpoint inhibitors as novel cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0442-6

Recent developments in the medical and surgical treatment of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0442-6

Nivolumab: a review of its use in patients with malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0442-6

The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: the Bristol-Myers Squibb experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0442-6

In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0442-6

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0442-6

Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0442-6

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0442-6

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0442-6

Nivolumab in previously untreated melanoma without BRAF mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0442-6

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0442-6

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0442-6

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0442-6

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0442-6

Management options for metastatic melanoma in the era of novel therapies: a primer for the practicing dermatologist: part I: Management of stage III disease

21 January 2018

1 reference

12 December 2020

Practical management of immune-related adverse events from immune checkpoint protein antibodies for the oncologist

1 reference

12 December 2020

BRAF mutations: signaling, epidemiology, and clinical experience in multiple malignancies

1 reference

12 December 2020

The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date

1 reference

12 December 2020

10.1007/S40265-015-0442-6

Identifiers

DOI

1 reference

PubMed ID

26220912

Dimensions Publication ID

4 September 2017

0 references

1 reference

PubMed ID

26220912